Opdivo (Nivolumab) 240mg Injection

Overview

Opdivo (Nivolumab) 240mg is a prescription immuno-oncology medicine containing Nivolumab, a monoclonal antibody administered by intravenous (IV) infusion under the supervision of an oncologist or qualified healthcare provider. It belongs to a class of drugs called PD-1 inhibitors (checkpoint inhibitors), which work by helping the body’s immune system recognize and attack cancer cells more effectively. Opdivo is manufactured by Bristol-Myers Squibb and is used in the treatment of various advanced-stage cancers, often as part of a broader oncology treatment plan.

Uses of Opdivo (Nivolumab) 240mg

Opdivo (Nivolumab) 240mg is prescribed for a range of cancers, depending on the stage and the patient’s treatment history, including:

• Advanced (metastatic) melanoma
• Non-small cell lung cancer (NSCLC)
• Advanced renal cell carcinoma (kidney cancer)
• Classical Hodgkin lymphoma
• Head and neck squamous cell carcinoma
• Urothelial carcinoma (bladder cancer)
• Colorectal cancer with specific genetic markers (MSI-H/dMMR)
• Hepatocellular carcinoma (liver cancer)
• Esophageal and gastric cancers (in certain settings)

Exact eligibility depends on prior treatment, biomarker status, and oncologist assessment — this medicine is strictly prescription-only and should never be self-administered.

How It Works

Opdivo (Nivolumab) 240mg blocks the PD-1 receptor on T-cells. Many cancer cells exploit this receptor to “hide” from the immune system. By blocking it, Opdivo restores the immune system’s ability to detect and destroy cancer cells.

Side Effects

As an immunotherapy, Opdivo (Nivolumab) 240mg works by activating the immune system, which can sometimes cause the immune system to attack healthy tissue. Common and serious side effects include:

Common:

• Fatigue
• Rash or itching
• Diarrhea
• Nausea
• Musculoskeletal pain
• Decreased appetite
• Serious (require immediate medical attention):
• Immune-related pneumonitis (lung inflammation)
• Colitis (severe diarrhea/abdominal pain)
• Hepatitis (liver inflammation)
• Endocrine disorders (thyroid, adrenal, pituitary dysfunction)
• Nephritis (kidney inflammation)
• Severe infusion reactions

Patients should be monitored closely throughout treatment, and any new or worsening symptoms should be reported to the treating physician immediately.

Benefits of Opdivo (Nivolumab) 240mg

Opdivo 240mg contains Nivolumab, a PD-1 inhibitor immunotherapy given by IV infusion to treat advanced cancers including melanoma, NSCLC, kidney cancer, Hodgkin lymphoma, and others. It works by helping the immune system recognize and attack cancer cells.Clinically proven to improve survival outcomes in several advanced cancers, Can be used as monotherapy or in combination with other therapies (e.g., Ipilimumab, chemotherapy).Broad approval across multiple cancer types, offering treatment options where other therapies have failed. Administered on a manageable infusion schedule (typically every 2–4 weeks)

Why Buy Opdivo 240mg from Dawailo.pk

• Genuine, DRAP-compliant sourcing — all oncology products are procured through verified, licensed channels
• Prescription verification process — ensures safe, compliant dispensing in line with Pakistani pharmaceutical regulations
• Cold-chain handling — biologics like Nivolumab require temperature-controlled storage and transport, which Dawailo.pk maintains from procurement to delivery
• Competitive pricing on high-cost oncology medication, with transparent invoicing
• Doorstep delivery across Karachi, Lahore, Islamabad, and other major cities
• Dedicated support team to assist with prescription queries and refill scheduling for ongoing cancer treatment

Disclaimer: Opdivo (Nivolumab) is a prescription-only oncology medication. This content is for informational purposes and does not replace consultation with a licensed oncologist. Dosage, eligibility, and treatment duration must be determined by the prescribing physician.